<DOC>
	<DOCNO>NCT01562678</DOCNO>
	<brief_summary>The main purpose study help u understand effect diabetes medication Liraglutide weight loss hunger . The investigator already determine high tolerate dose Liraglutide early human research study . Liraglutide approve FDA January 2010 treatment diabetes . The investigator also study follow : 1 . The impact Liraglutide brain response food 2 . It 's effect physiological mental performance 3 . If effect brain differs among obese lean diabetic subject .</brief_summary>
	<brief_title>Liraglutide Obesity Diabetes : Identification CNS Targets Using fMRI</brief_title>
	<detailed_description>This randomize , placebo control , cross-over , double-blinded study ass effect liraglutide brain activation area involve cognitive control reward food visualization . Study participation span approximately 1.5-2 month . Subjects learn self-administer medication total 8 study visit plus one screening visit . The visit include follow tests/procedures : 1 . Vital sign ( blood pressure , temperature , heart rate , breathe rate ) 2 . Height , weight body measurement like waist 3 . Blood test 4 . Urine pregnancy test ( woman ) 5 . Electrocardiogram ( EKG ) 6 . Medical history 7 . Physical exam 8 . Body Composition test 9 . Study log record food intake blood sugar 10. functional MRI We plan recruit total 24 subject treat placebo liraglutide . We propose enroll 12 obese diabetic ( type 2 ) 12 lean diabetic ( type 2 ) subject . Equal number men woman enrol randomization block gender .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Subjects men woman age 18 65 . The follow table list inclusion criterion group ( lean diabetic obese diabetic ) . Subjects must meet either HbA1c fast plasma glucose ( FPG ) criterion . Lean diabetic : BMI : 1825 kg/m2 HbA1c : &lt; 8.9 % Fasting plasma glucose : &lt; 250 mg/dL Other inclusion criterion : On dietary modification and/or metformin Obese diabetic : BMI : &gt; 27 kg/m2 HbA1c : &lt; 8.9 % Fasting plasma glucose : &lt; 250 mg/dL Other inclusion criterion : On dietary modification and/or metformin Additionally , woman participant must use double barrier method prevent pregnancy ( diaphragm intravaginal spermicide , cervical cap , male female condom spermicide ) . If woman suspect become pregnant time use one contraceptive method recommend investigator , must notify study staff . If woman become pregnant , withdrawn study . The study staff follow progress pregnancy birth child . 1 . Uncontrolled diabetes ( HbA1c &gt; 8.9 % , FPG &gt; 250 mg/dL ) 2 . Women breastfeed , pregnant , want become pregnant . 3 . Women use IUD 4 . Any change dosage hormonal contraceptive medication ( birth control pill , implanon ) . Subjects remain medication/ dose time entire study . 5 . Moderate ( creatinine clearance 3059 ml/min ) severe renal impairment ( creatinine clearance 30 ml/min ) endstage renal disease 6 . Moderate , severe hepatic impairment 7 . Hypersensitivity active substance excipients liraglutide 8 . History diabetic ketoacidosis 9 . Congestive heart failure 10 . Inflammatory condition like inflammatory bowel disease , Rheumatoid arthritis etc 11 . Gastroparesis 12 . Pancreatitis 13 . Gallstones may cause increase risk pancreatitis 14 . Alcohol consumption maximum quantity men 140g—210g per week . For woman , range 84g—140g per week drink consume two drink day men one woman . Alcohol cause increase risk pancreatitis hypoglycemia . 15 . Untreated thyroid disease like hypothyroidism hyperthyroidism 16 . Subjects take following medication : warfarin , steroid ( inhaled systemic due reduce hypoglycemic effect ) , subject hormone ( LHRH analogs etc ) . 17 . Subjects oral antidiabetic agent except metformin 18 . Personal family history MEN II medullary thyroid cancer 19 . Subjects type bioimplant activate mechanical , electronic , magnetic mean ( e.g . cochlear implant , pacemaker , neuron biostimulators , electronic infusion pump , etc . ) 20 . Subjects type metallic implant could potentially displace damaged MRI , aneurysm clip , metallic skull plate , surgical implant etc . metal contain tattoo 21 . Anxiety and/or claustrophobia 22 . Uncontrolled cardiac impairment , circulatory impairment , inability perspire ( poor thermoregulatory function ) 23 . Significant sensory motor impairment 24 . Epilepsy , particularly photosensitive epilepsy , may place individual high risk adverse event fMRI scan visual stimulation 25 . Subjects neurological problem may interfere complicate testing ( e.g . presence titubation ) 26 . Body weight limitation MRI scan table ( 330lbs/150 Kg ) body dimension could difficult performance scan . 27 . Subjects adhere experimental protocol reason 28 . Anemia Hgb less 10 29 . Uncontrolled infectious disease ( e.g . HIV , hepatitis , chronic infection etc ) 30 . Any uncontrolled endocrine condition , e.g Cushing 's , Acromegaly , etc 31 . Any cancer lymphoma 32 . Eating disorder like anorexia , bulimia 33 . Severe hypertriglyceridemia ( triglyceride &gt; 500 mg/dl ) 34 . Weight loss surgery gastrectomy 35 . Any change medication affect brain function , e.g . antidepressant , antipsychotic , antianxiety , antiseizure medication , antihypertensive etc ( subject remain medication/ dose time entire study ) . 36 . Irregular period , define cycle length le 22 day 40 day . 37 . Any change smoking status . 38 . Vegetarians food image present include numerous nonvegetarian item thus appeal high calorie food item .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>fMRI</keyword>
	<keyword>Liraglutide</keyword>
	<keyword>diabetes</keyword>
	<keyword>GLP-1</keyword>
</DOC>